{"title":"戊烯酸通过改善下丘脑酪氨酸羟化酶和组胺- n -甲基转移酶改善安非他明相关的神经毒性","authors":"Khaled M.M. Koriem , Ammar H.A. Naiem","doi":"10.1016/j.toxrep.2025.101936","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Narcolepsy, obesity, and attention deficit hyperactivity disorder are all treated with amphetamine (a central nervous system stimulant) while valerenic acid (VA) has a pharmacological effect in the central nervous system.</div></div><div><h3>Objectives</h3><div>The purpose of this study was to ascertain whether VA is able to make amends for neurotoxicity by modifying hypothalamus expressions of the enzymes <em>tyrosine hydroxylase and histamine-N-methyl transferase</em> in rats orally administered with methamphetamine (METH).</div></div><div><h3>Methods</h3><div>There were thirty-six male albino rats split up into six equal groups, Control, VA (5 mg/kg)-treated, and VA (10 mg/kg)-treated groups: For four weeks, normal rats received oral administration of 1 ml of distilled water, 5 mg/kg of VA, and 10 ml/kg of VA once daily. METH-treated, VA (5 mg/kg) prior to METH-treated, and VA (10 mg/kg) before METH-treated groups: normal rats were oral administrated with METH (2.5 mg/kg), 3 days/week for 3 weeks, where the last two groups were oral administrated daily during four weeks at 5 mg/kg and 10 mg/kg VA, starting one week prior to METH administration.</div></div><div><h3>Results</h3><div>METH decreased superoxide dismutase, glutathione peroxidase, catalase, NADPH oxidase, interleukin-10, sucrose preference test, distance traveled test, and center square entries test, ATPase activity and the enzymes <em>tyrosine hydroxylase</em> and <em>histamine-N-methyl transferase</em> but increased malondialdehyde, conjugated dienes, oxidative index, serotonin, dopamine, norepinephrine, γ-aminobutyric acid, tumor necrosis factor-α, interleukin-1β, interleukin-6, nuclear factor kappa B levels, the center square duration test, tail suspension test, and forced swimming test. in the METH-treated animals' brain in contrast to the control group. After four weeks of oral administration of VA to METH-treated rats, all of these parameters returned to levels that were nearly control, indicating that a higher dose was more effective than a lower one.</div></div><div><h3>Conclusion</h3><div>VA ameliorated METH-related neurotoxicity by improving hypothamalus expressions of the enzymes <em>tyrosine hydroxylase</em> and <em>histamine-N-methyl transferase</em>.</div></div>","PeriodicalId":23129,"journal":{"name":"Toxicology Reports","volume":"14 ","pages":"Article 101936"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Valerenic acid ameliorates amphetamine-related neurotoxicity by improving hypothalamus tyrosine hydroxylase and histamine-N-methyl transferase enzymes\",\"authors\":\"Khaled M.M. Koriem , Ammar H.A. Naiem\",\"doi\":\"10.1016/j.toxrep.2025.101936\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Narcolepsy, obesity, and attention deficit hyperactivity disorder are all treated with amphetamine (a central nervous system stimulant) while valerenic acid (VA) has a pharmacological effect in the central nervous system.</div></div><div><h3>Objectives</h3><div>The purpose of this study was to ascertain whether VA is able to make amends for neurotoxicity by modifying hypothalamus expressions of the enzymes <em>tyrosine hydroxylase and histamine-N-methyl transferase</em> in rats orally administered with methamphetamine (METH).</div></div><div><h3>Methods</h3><div>There were thirty-six male albino rats split up into six equal groups, Control, VA (5 mg/kg)-treated, and VA (10 mg/kg)-treated groups: For four weeks, normal rats received oral administration of 1 ml of distilled water, 5 mg/kg of VA, and 10 ml/kg of VA once daily. METH-treated, VA (5 mg/kg) prior to METH-treated, and VA (10 mg/kg) before METH-treated groups: normal rats were oral administrated with METH (2.5 mg/kg), 3 days/week for 3 weeks, where the last two groups were oral administrated daily during four weeks at 5 mg/kg and 10 mg/kg VA, starting one week prior to METH administration.</div></div><div><h3>Results</h3><div>METH decreased superoxide dismutase, glutathione peroxidase, catalase, NADPH oxidase, interleukin-10, sucrose preference test, distance traveled test, and center square entries test, ATPase activity and the enzymes <em>tyrosine hydroxylase</em> and <em>histamine-N-methyl transferase</em> but increased malondialdehyde, conjugated dienes, oxidative index, serotonin, dopamine, norepinephrine, γ-aminobutyric acid, tumor necrosis factor-α, interleukin-1β, interleukin-6, nuclear factor kappa B levels, the center square duration test, tail suspension test, and forced swimming test. in the METH-treated animals' brain in contrast to the control group. After four weeks of oral administration of VA to METH-treated rats, all of these parameters returned to levels that were nearly control, indicating that a higher dose was more effective than a lower one.</div></div><div><h3>Conclusion</h3><div>VA ameliorated METH-related neurotoxicity by improving hypothamalus expressions of the enzymes <em>tyrosine hydroxylase</em> and <em>histamine-N-methyl transferase</em>.</div></div>\",\"PeriodicalId\":23129,\"journal\":{\"name\":\"Toxicology Reports\",\"volume\":\"14 \",\"pages\":\"Article 101936\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Toxicology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S221475002500054X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Environmental Science\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxicology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221475002500054X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Environmental Science","Score":null,"Total":0}
引用次数: 0
摘要
发作性睡病、肥胖和注意缺陷多动障碍都可以用安非他明(一种中枢神经系统兴奋剂)治疗,而戊酸(VA)对中枢神经系统有药理作用。目的:本研究的目的是确定VA是否能够通过改变口服甲基苯丙胺(METH)大鼠下丘脑酪氨酸羟化酶和组胺- n -甲基转移酶的表达来弥补神经毒性。方法雄性白化病大鼠36只,随机分为对照组、VA(5 mg/kg)组和VA(10 mg/kg)组,正常大鼠口服蒸馏水1 ml、VA 5 mg/kg、VA 10 ml/kg,每天1次,连续4周。甲基苯丙胺处理组,甲基苯丙胺处理组之前的VA(5 mg/kg)和甲基苯丙胺处理组之前的VA(10 mg/kg):正常大鼠口服甲基苯丙胺(2.5 mg/kg),每周3天,连续3周,后两组在甲基苯丙胺给药前一周开始,连续四周每天口服5 mg/kg和10 mg/kg甲基苯丙胺。结果甲氧苄胺降低了超氧化物歧化酶、谷胱甘肽过氧化物酶、过氧化氢酶、NADPH氧化酶、白细胞介素-10、蔗糖偏好试验、距离旅行试验、中心方点试验、atp酶活性、酪氨酸羟化酶和组胺- n-甲基转移酶活性,提高了丙二醛、偶联二烯、氧化指数、血清素、多巴胺、去甲肾上腺素、γ-氨基丁酸、肿瘤坏死因子-α、白细胞介素-1β、白细胞介素-6、核因子κ B水平。中心方形持续时间试验,尾悬试验,强迫游泳试验。与对照组相比,服用甲基苯丙胺的动物大脑中给服用甲基苯丙胺的大鼠口服VA 4周后,所有这些参数都恢复到接近控制的水平,表明高剂量比低剂量更有效。结论va通过改善下丘脑酪氨酸羟化酶和组胺- n -甲基转移酶的表达,改善了冰毒相关的神经毒性。
Valerenic acid ameliorates amphetamine-related neurotoxicity by improving hypothalamus tyrosine hydroxylase and histamine-N-methyl transferase enzymes
Background
Narcolepsy, obesity, and attention deficit hyperactivity disorder are all treated with amphetamine (a central nervous system stimulant) while valerenic acid (VA) has a pharmacological effect in the central nervous system.
Objectives
The purpose of this study was to ascertain whether VA is able to make amends for neurotoxicity by modifying hypothalamus expressions of the enzymes tyrosine hydroxylase and histamine-N-methyl transferase in rats orally administered with methamphetamine (METH).
Methods
There were thirty-six male albino rats split up into six equal groups, Control, VA (5 mg/kg)-treated, and VA (10 mg/kg)-treated groups: For four weeks, normal rats received oral administration of 1 ml of distilled water, 5 mg/kg of VA, and 10 ml/kg of VA once daily. METH-treated, VA (5 mg/kg) prior to METH-treated, and VA (10 mg/kg) before METH-treated groups: normal rats were oral administrated with METH (2.5 mg/kg), 3 days/week for 3 weeks, where the last two groups were oral administrated daily during four weeks at 5 mg/kg and 10 mg/kg VA, starting one week prior to METH administration.
Results
METH decreased superoxide dismutase, glutathione peroxidase, catalase, NADPH oxidase, interleukin-10, sucrose preference test, distance traveled test, and center square entries test, ATPase activity and the enzymes tyrosine hydroxylase and histamine-N-methyl transferase but increased malondialdehyde, conjugated dienes, oxidative index, serotonin, dopamine, norepinephrine, γ-aminobutyric acid, tumor necrosis factor-α, interleukin-1β, interleukin-6, nuclear factor kappa B levels, the center square duration test, tail suspension test, and forced swimming test. in the METH-treated animals' brain in contrast to the control group. After four weeks of oral administration of VA to METH-treated rats, all of these parameters returned to levels that were nearly control, indicating that a higher dose was more effective than a lower one.
Conclusion
VA ameliorated METH-related neurotoxicity by improving hypothamalus expressions of the enzymes tyrosine hydroxylase and histamine-N-methyl transferase.